|
Post by itellthefuture777 on Sept 11, 2017 10:41:07 GMT -5
|
|
|
Post by kbrion77 on Sept 11, 2017 10:44:48 GMT -5
Sorry to burst your bubble but investment amount and current value are completely different. At this point in time nobody in their right mind would buy that facility for $168MM.
|
|
|
Post by dreamboatcruise on Sept 11, 2017 10:48:06 GMT -5
A couple of points I found interesting.
- Said that they put efforts to get more insurers signed up on hold pending the label change, which if successful would allow them to use different strategy and pricing. (Hopefully there would still be time to get on 2018 formularies)
- Patents covering Afrezza extend to 2032 and even then it would be very difficult to replicate Afrezza.
|
|
|
Post by brotherm1 on Sept 11, 2017 11:02:37 GMT -5
good stuff I missed. thank you
|
|
|
Post by BlueCat on Sept 11, 2017 11:09:10 GMT -5
Solid presentation.
Glad to see he is trying to clarify how sales are being measured.
If I understood correctly - he's doing it by cartridges, rather than scripts (other than tracking the Nrx to Trx ratio).
However - wouldn't it make more sense to do it by units of insulin? If the packaging changes (cartridge sizes, etc), wouldn't that impact the numbers - and make it an apples/oranges?
He delivered I think on (2.5) of the four big questions - sales traction and pipeline choices. We have a little bit on the partnerships. We don't have any clarity on the financial recap strategy.
|
|
|
Post by MnkdWASmyRtrmntPlan on Sept 11, 2017 11:10:15 GMT -5
A couple of points I found interesting. - Said that they put efforts to get more insurers signed up on hold pending the label change, which if successful would allow them to use different strategy and pricing. (Hopefully there would still be time to get on 2018 formularies) - Patents covering Afrezza extend to 2032 and even then it would be very difficult to replicate Afrezza. Yes, both very interesting. Also, they did a market study and found that 98% of T1 and T2 PWD have never heard of Afrezza. I'm climbing in the back seat of ITell's rocket because this ship still has the same potential it did 11-12 years ago when it was over $100/sh in today's post-split terms (yes, that's a 50-bagger)
|
|
|
Post by sportsrancho on Sept 11, 2017 11:20:58 GMT -5
Great call! I'm glad he did extra research and knows only 2% know about Afrezza. The Ped trial has started end of Aug. My fave:-)
I didn't hear the questions. Can someone tell me what they were, and who asked them?
|
|
|
Post by agedhippie on Sept 11, 2017 11:22:46 GMT -5
We are sitting on a rocket..$168 million dollar factory owned by mnkd exceeds the market cap... You do realize that the factory is security for the Deerfield loans so it cannot be sold until Deerfield is paid off don't you? In other words we have already spent the money.
|
|
|
Post by mnkdfann on Sept 11, 2017 11:27:33 GMT -5
We are sitting on a rocket..$168 million dollar factory owned by mnkd exceeds the market cap... You do realize that the factory is security for the Deerfield loans so it cannot be sold until Deerfield is paid off don't you? In other words we have already spent the money. So why does Mike keep bringing it up?
|
|
|
Post by therealisaching on Sept 11, 2017 11:40:26 GMT -5
We are sitting on a rocket..$168 million dollar factory owned by mnkd exceeds the market cap... You do realize that the factory is security for the Deerfield loans so it cannot be sold until Deerfield is paid off don't you? In other words we have already spent the money. Deerfield can lift their lien anytime they want. Their best chance of having their debt paid in full is for the company to survive and thrive. If there is enough value here to complete a sale leaseback I'd expect some of the proceeds to paydown Deerfield debt as part of the transaction. A liquidation of the company in bk isnt going to make them whole. I can see them continuing their pattern of rolling some debt and taking some payments.
|
|
|
Post by slugworth008 on Sept 11, 2017 11:41:21 GMT -5
Very nice presentation by Michael C just now. Reaffirms why I invested in this company. So glad he is our CEO and I have high hopes for MNKD & Afrezza with him at the helm. Such a change from a year ago! Afrzza is going to prevail and it will become the new standard treatment of care for diabetics worldwide. Big changes coming Crew, and injectable insulin is going to lose market share to Afrezza. Aloha. I totally agree with you. Such a refreshing change from a year ago. Love this guy !!! Kudos to Matt for bringing him on too !!!
|
|
|
Post by itellthefuture777 on Sept 11, 2017 11:41:22 GMT -5
Solid presentation. Glad to see he is trying to clarify how sales are being measured. If I understood correctly - he's doing it by cartridges, rather than scripts (other than tracking the Nrx to Trx ratio). However - wouldn't it make more sense to do it by units of insulin? If the packaging changes (cartridge sizes, etc), wouldn't that impact the numbers - and make it an apples/oranges? He delivered I think on (2.5) of the four big questions - sales traction and pipeline choices. We have a little bit on the partnerships. We don't have any clarity on the financial recap strategy. caridge to profit per cartridge is exponentially higher..nice!
|
|
|
Post by joeypotsandpans on Sept 11, 2017 11:44:30 GMT -5
We are sitting on a rocket..$168 million dollar factory owned by mnkd exceeds the market cap... You do realize that the factory is security for the Deerfield loans so it cannot be sold until Deerfield is paid off don't you? In other words we have already spent the money. You do realize that Deerfield continues to work with restructuring covenants and terms and collateral can be financed to help restructure one's finances if the creditor is willing? They have shown/demonstrated they are willing to work with the company. So if Mike is pointing in that direction my bet would be he has already had discussions regarding same, especially if it improves the financial condition of the company improving the s/p of which Deerfield does hold a position.
|
|
|
Post by brotherm1 on Sept 11, 2017 11:49:20 GMT -5
Mike slams it!..drops the mic..awesome!! But, In his post presentation q and a, when asked about recapitalization, he said that he would "not give any details on that right this second, sorry". My take...Okay, possibly waiting for a final label verdict from the FDA. or possibly something that he is unable to announce for other reasons. IDK Then asked if he was looking for capital or getting rid of debt, (inaudible) equity? Mike responds, "we have a manufacturing plant that we own...we have partners there, so theres a lot of ways to capitalize the company" So I ask...We do? Who are our partners? Anyone know? Yet, Still in the dark... Sounded to me like he said "partner there" when referring to the plant snd capitalization. Only partner I'm aware of there is RLS who has access to the facility.
|
|
|
Post by itellthefuture777 on Sept 11, 2017 11:50:14 GMT -5
We are sitting on a rocket..$168 million dollar factory owned by mnkd exceeds the market cap... You do realize that the factory is security for the Deerfield loans so it cannot be sold until Deerfield is paid off don't you? In other words we have already spent the money. I know Al personally put a billion of his own money into developing and bringing to market Afrezza...his IQ 176...and passion to help humankind and the hundreds of millions of diabetics...is moving forward in Mike's hands now...going into commercialisation with largest sales ever possible on Friday..even with a hurricane..a holiday...and yet..exceeding expectations...stock potential = up imo long Mnkd! Good job Mike!!
|
|